• 1 Department of Internal Medicine, University of Medicine and Pharmacy, Hue University, Hue, Vietnam
  • 2 Departement of Internal Medicine, University of Medicine, Vinh University, Vinh, Vietnam
  • 3 Departement of Cardiology, Hue Central Hospital, Hue, Vietnam
  • 4 Institute of Public Health and Community Medicine Research Center, National Yang-Ming University School of Medicine, Taipei, Taiwan
  • 5 Department of General Medicine, Tan Tock Seng Hospital, Singapore City, Singapore
  • 6 Punjab Medical Center, Lahore, Pakistan
  • 7 Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan
  • 8 MIOT International Hospital, Chennai, India
  • 9 Department of Primary Care Medicine, Faculty of Medicine, University of Malaya Kuala, Lumpur, Malaysia
  • 10 Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan
J Clin Hypertens (Greenwich), 2021 03;23(3):529-537.
PMID: 33415834 DOI: 10.1111/jch.14155


Insulin resistance (IR), a metabolic risk factor, is linked to the pathogenetic mechanism of primary hypertension. Detecting IR in the patients with hypertension will help to predict and stratify the added cardiovascular risk, institute appropriate IR management, and manage hypertension optimally. There are many methods for assessing IR, each with distinct advantages and disadvantages. The euglycemic insulin clamp and intravenous glucose tolerance test, gold standards for measuring IR, are used in research but not in clinical practice. Homeostatic model assessment (HOMA-IR), a method for assessing β-cell function and IR, is frequently applied presently, particularly in Asia. Besides, the triglyceride-glucose index (TyG) first published by South American authors showed a good correlation with the insulin clamp technique and HOMA-IR index. This simple, convenient, and low-cost TyG index is of research interest in many countries in Asia and can be used to screen for IR in the Asian hypertensive community.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.